Journal
MOVEMENT DISORDERS
Volume 31, Issue 10, Pages 1535-1542Publisher
WILEY
DOI: 10.1002/mds.26754
Keywords
Parkinson's disease; alpha-synuclein; oligomers; biomarkers; DATATOP
Categories
Funding
- Michael J. Fox Foundation for Parkinson's Research (New York)
- Grants-in-Aid for Scientific Research [15K09322] Funding Source: KAKEN
Ask authors/readers for more resources
BackgroundParkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease-modifying therapies. In this article, we investigated the longitudinal changes of CSF -synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. MethodsWe used our newly developed enzyme-linked immunosorbent assay systems for measuring different forms of -synuclein, such as oligomeric--synuclein, phosphorylated--synuclein at serine 129, or total--synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n=121). CSF Alzheimer's disease biomarkers (total-tau, phosphorylated-tau, A(40), and A(42)) were also measured for this cohort. ResultsInterestingly, total--synuclein and oligomeric--synuclein levels significantly increased during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow-up period, whereas phosphorylated--synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric--synuclein/total--synuclein ratio and a worsening of motor signs, in particular in the postural-instability and gait-difficulty dominant PD group. A strong positive correlation between the changes in CSF total--synuclein and oligomeric--synuclein during the 2-year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r=0.84, P<.001). ConclusionOur data show that CSF -synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes. (c) 2016 International Parkinson and Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available